publication venue for
- Red blood cell distribution width as an easily measurable biomarker of persistent inflammation and T cell dysregulation in antiretrovirally treated HIV-infected adults.. 19. 2018
- Sofosbuvir in the treatment of early HCV infection in HIV-infected men.. 18. 2017
- Non-classical monocytes predict progression of carotid artery bifurcation intima-media thickness in HIV-infected individuals on stable antiretroviral therapy.. 17. 2016
- Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.. 17. 2016
- Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US.. 16. 2015
- Corrigendum. Hepatic Safety in Subjects With HIV-1 and Hepatitis C and/or B Virus: A Randomised, Double-Blind Study of Maraviroc vs Placebo in Combination With Antiretroviral Agents.. 16. 2015
- Serum amyloid P (SAP) is associated with impaired brachial artery flow-mediated dilation in chronically HIV-1 infected adults on stable antiretroviral therapy.. 16. 2015
- Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.. 16. 2015
- Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial.. 14. 2013
- Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.. 14. 2013
- High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine.. 14. 2013
- Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.. 14. 2013
- Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.. 13. 2012
- Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients.. 13. 2012
- Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis.. 12. 2011
- Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164.. 11. 2010
- A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.. 11. 2010
- Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.. 11. 2010
- Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).. 10. 2009
- Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers.. 10. 2009
- Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.. 9. 2008
- Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.. 9. 2008
- Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.. 8. 2007
- In vivo assessment of antiviral reactivity in chronic HIV infection.. 1. 2000
- Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.. 1. 2000